XRP, after defending its first major support zone, is now approaching a critical technical threshold. Trading at approximately $1.06, the crypto asset remains above the $0.98–$0.99 region. However, indicators suggest that the overall technical weakness has not yet been fully resolved.
XRP holds above $0.98 support, but analysts warn recovery needs breakout over $1.16
Technical landscape: $1.16 stands out as a turning point
According to market research platform More Crypto Online, XRP’s broader structure remains tilted downward. The platform highlights that simply holding the support zone is not enough to confirm a sustained recovery; reclaiming stronger resistance levels is needed for such confirmation. Noted for its focus on wave-based technical analysis, More Crypto Online’s observations suggest the bear trend persists unless key levels are surpassed.
More Crypto Online emphasizes that the bearish structure in XRP can only be significantly weakened if the price decisively breaks above $1.16. Such a move could technically confirm a wider second wave of recovery.
According to Elliott Wave analysis, the main scenario still sees a risk of further pullback. The $0.98–$0.99 range is being watched as the first significant demand zone, and unless there is a clear move above $1.16, the downside structure remains in place.
Mini glossary: Elliott Wave analysis is a technical approach linking price patterns to investor psychology, interpreting market movements through wave structures. The method uses support and resistance levels to project likely next moves in price.
| $1.16 | First critical resistance that could weaken the bearish outlook |
| $1.27–$1.42 | Supply zone where stronger selling pressure may emerge |
| $0.98–$0.99 | Primary support and demand zone |
| $0.74 | Next major level to watch if support breaks |
Seller resistance persists despite short-term rebound
Even if XRP sees a short-term uptick, a stronger resistance zone lies between $1.27 and $1.42. This area is considered a key supply region, where sellers may reassert themselves. If the price fails to break through this band, any upward movement is expected to be interpreted as a brief relief rally rather than a lasting trend reversal.
While XRP has defended its support, current buying activity does not appear strong enough to completely negate the downtrend scenario.
Downside risks: eyes on the $0.74 level
If the $0.98–$0.99 support zone is breached, renewed selling pressure could intensify. In this case, a pullback toward $0.74 could come into play, which More Crypto Online identifies as the next crucial support area.
As a result, market focus is converging around two key levels. A move above $1.16 could signal improvement in the technical outlook, while losing the current support would increase the probability of a deeper correction.
Moreover, XRP has historically shown robust performance in July, with past seasonal trends occasionally giving buyers an edge in the short term. Still, unless major resistance levels are broken, the overall technical picture remains cautious, urging patience among traders.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

